Chennai-based drug manufacturer Orchid Chemicals & Pharmaceuticals has received the final Abbreviated New Drug Application (ANDA) nod from the US Food and Drug Administration for its Zaleplon capsules.   
 
The capsules which are available in strengths of 5 mg and 10 mg, are used in treating insomnia.

With this approval, the total ANDA approval count of Orchid has gone up to 37 while, the total ANDA filings stand at 58.     

Two days earlier, Orchid has received the US drug regulator's nod for its Piperacillin and Tazobactam injection, which are used to treat infections caused by certain bacteria.

The scrip of the company closed today at Rs 163 on BSE. The counter has made 52-week-high and low of Rs 228 and Rs 56 respectively.